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INTRODUCTION 
 
 Acute flaccid paralysis  is a potentially reversible medical emergency and 
has a wide differential diagnosis that includes neurologic, metabolic and 
infectious etiologies. Acute hypokalemic paralysis (HP) constitutes a group of 
heterogenous disorders that present with acute muscular weakness and can at 
times be potentially life threatening1.  Complications secondary to hypokalemia 
such as a cardiac arrhythmia or respiratory failure lead to morbidity and 
mortality. Although there are many potential causes of hypokalemia, there are 
far fewer entities in the differential diagnosis of hypokalemic paralysis. 
Hypokalemia and paralysis can be divided into 2 types, hypokalemic periodic 
paralysis (HPP) where there is short-term shift of potassium into cells and non-
HPP resulting from a large deficit of potassium due to various etiologies. The 
differential diagnosis in a patient with HP can be challenging due to 
heterogeneity of its etiologies, but it is important to make the diagnosis promptly 
because different therapies are required for each type and identifying causes that 
are reversible are important2. Presence of a positive family history and recurrent 
episodes in a patient  can be helpful in making a diagnosis of  HPP , but HPP 
and non-HPP are almost  indistinguishable and there is diagnostic difficulty2.   
 Familial periodic paralysis has been reported as the most common cause 
of hypokalemic paralysis in Caucasians. Thyrotoxic hypokalemic paralysis 
(TPP) is common in the Asian (oriental) population. The etiology of 
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hypokalemic paralysis is likely to depend on ethnicity, vigor of the investigation, 
and the setting of the medical practice3.  
In this study an attempt has been made to analyze the various etiologies 
of HP that appears to be common in our region. We have also analyzed the 
metabolic profile that will aid in diagnosis and outcome of patients with 
hypokalemic paralysis. 
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AIM 
 
 
 To analyze the clinical presentation, etiology, and outcome of patients 
presenting with hypokalemic paralysis. 
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Review of Literature 
 Claude Bernard wrote that ‘the constancy of the internal milieu is the 
essential condition to a free and independent life’. Potassium is the most 
abundant cation in the human body, with total body stores amounting to 50 
mmol/kg in adults. Less than 2% of K+ is located extracellularly, and kalaemia is 
maintained in the narrow range of 3.5–5.0 mmol/L. Normal individuals ingesting 
80–100 mmol of K+ daily remain in balance by virtue of short-term transcellular 
K+ shifts regulated by insulin, aldosterone and β-adrenergic catecholamines (β2 
receptors), which increase the cellular K+ uptake by stimulating the sodium 
pump (Na+/K+-ATPase), and the excretion of 90% of the ingested K+ in the urine 
and the remaining in stool.4  
 
Fig15 
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Figure 2 | Cellular shifts in K+. A simplified diagram showing the important 
transporters involved in K+ distribution across cell membranes, including the 
Na+,K+-ATPase ‘sodium pump’, K+ channels and NHE. Substances that act on 
these channels and transporters to induce cellular shifts in K+ are also shown. 
Abbreviations: α-AR, α-adrenergic receptor; β2-AR, β2-adrenergic receptor; AR, 
aldosterone receptor; H+, hydrogen; K+, potassium; Na+, sodium; NHE,Na+/H+ 
exchanger. 
Fig 2 5 
 
Hypokalemia is common in patients who are ill, have a fever or are 
malnourished, including those with eating disorders, alcoholism or AIDS. 
Women develop hypokalemia more often than men, especially when given 
thiazide diuretics; the increased susceptibility of women to hypokalemia is 
probably related to reduced muscle mass and a smaller pool of exchangeable 
K+.5 
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The most prominent clinical features of hypokalemia or potassium 
depletion are neuromuscular, although other systems, such as cardiovascular and 
gastrointestinal, may also be affected. Some patients complain of muscular 
weakness, especially of the lower extremities, while marked and generalized 
weakness of skeletal muscles is common with more severe potassium depletion. 
Very severe hypokalaemia may lead to virtually total paralysis including 
respiratory, bulbar and cranial musculature. Deaths from respiratory failure and 
arrhythmia have been reported. 
 
Differential diagnosis of hypokalaemic paralysis (modified  from ref 6) 
Transcellular distribution of K (no depletion) 
• Familial periodic paralysis 
• Thyrotoxic periodic paralysis 
• Barium poisoning 
Actual K depletion 
Renal loss 
• RTAs 
• Sjögren’s syndrome 
• Medullary sponge kidney 
• Chronic toluene exposure 
• Fanconi’s syndrome 
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• Tubulointerstitial disorder, Gitelman syndrome, Barrter syndrome 
• Primary hyperaldosteronism 
• Drug-induced: Gentamicin, carbenicillin, amphotericin B, degraded 
tetracycline, vitamin B12, alcohol, carbenoxolone, overdoses of 
chloroquine, the antipsychotic agents risperidone or quetiapine9 
• Others - water intoxication, nephrotic syndrome,diuretic phase of acute 
tubular necrosis, treatment phase of diabetic ketoacidosis, chlorothiazide-
associated hypokalaemia, hypokalaemia following ureterosigmoidostomy 
, Licorice6 consumption, Leptospirosis18, Cleistanthus collinus 
poisoning.19 
Extra-renal loss 
• Celiac disease 
• Tropical sprue 
• Acute gastroenteritis 
• Short bowel syndrome 
 
Hypokalemic periodic paralysis 
 Ion channels constitute a class of proteins that is ultimately responsible 
for generating and orchestrating the electrical signals passing through the 
thinking brain, the beating heart, and the contracting muscle. Defective  ion-
channel proteins are responsible for cystic fibrosis, the long-QT syndrome, 
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heritable hypertension (Liddle’s syndrome), familial persistent hyperinsulinemic 
hypoglycemia of infancy, hereditary nephrolithiasis (Dent’s disease), and a 
variety of hereditary myopathies, including generalized myotonia (Becker’s 
disease), myotonia congenita (Thomsen’s disease), periodic paralyses, malignant 
hyperthermia, and central core storage disease7 . 
 
The periodic paralyses, paradigm for muscle channelopathies  
 The periodic paralyses are rare and dominantly inherited disorders 
characterized by neuromuscular symptoms  (paralysis and myotonia) associated 
with marked and transitory variations of K+ levels in the plasma 8 . Symptoms 
usually appear during the first or second decade  of life and can be life-
threatening if heart or respiratory  muscles are involved.  
 
Familial Hypokalemic periodic paralysis 
Nomenclature  
  Hypokalemic periodic paralysis  was also known as Cavare-Romberg 
syndrome, Cavare-Westphal syndrome, Cavare-Romberg-Westphal syndrome, 
Westphal's disease, Westphal's neurosis . Karl Friedrich Otto Westphal (1833-
1890) first described extensively and convincingly the main characteristics of the 
disease, which had previously been described as "periodic palsy" by Musgrave 
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in 1727, Cavare in 1853, and Romberg in 1857. Hartwig reported a case of palsy 
with muscle inexcitability provoked by rest after exercise in 1875. It was not 
until 1887 that a dominant pedigree was described by Cousot10. 
Ion channels involved 11 
Sodium channel 
 Hypokalemic PP (HypoPP2) 
Calcium channel 
  Hypokalemic PP (HypoPP1) 
Potassium channel 
 Andersen-Tawil syndrome 
 (Hyperkalemic PP or hypokalemic PP) 
Prevalence 12 
 The prevalence of HOKPP is unknown but thought to be approximately 
1:100,000. Inheritance is autosomal dominant with reduced penetrance in 
women. Symptoms begin early in life and rarely after the age of 25 years. 
Typically affects Caucasians with male preponderance. Male to female ratio is 
3:1.2 Age of onset was earlier and the duration of episodes was longer in 
HypoPP1 (10 years; 20 h) versus HypoPP2 (16 years;1 h).  
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Genetics and Inheritance 10 
Calcium Channel – 
• Voltage-Dependent, L Type, 
•  Skeletal Muscle Dihydropyridine-Sensitive, Alpha-1 Subunit;  
• CACNA1S Gene map locus 1q32 
• Seven Mutations described to Date: ARG1239HIS, ARG528HIS , 
ARG528GLY , ARG1239GLY , ARG1086CYS & ARG1086HIS  
Sodium Channel –  
• Voltage-Gated, Type IV,  
• Alpha Subunit;  
• SCN4A; Gene map locus 17q23.1-q25.3 
• Six mutations described to date: ARG669HIS , ARG672HIS, 
ARG672GLY , ARG672SER , DIII-S4 ARG1132Q and alpha subunit, 
between 4th/5th transmembrane segments, domain III SCN4A, 
Pro1158Ser. 
 Potassium channel-  
• Inward-rectifying potassium channel Kir2.1   
• KCNJ2 gene; Gene map locus 17q24.3;  
• More than 20 mutations described 
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Pathophysiology 
 
 The pathophysiology behind the disorder is poorly understood. This is a 
type of skeletal muscle channelopathy. Several mutations have been reported in 
skeletal muscle  dihydropyridine receptor calcium channel(CACNL1A3), 
tetrodoxin sensitive voltage sensitive sodium channel(SCN4A) and potassium 
channel(Kir2.1). However sporadic cases without documented evidence of 
mutation have been reported8.  
 Cav1.1 is the main subunit of the voltage-gated pentameric L type Ca2+ 
channel complex (also called the dihydropyridine receptor) located in the 
transverse (t) tubular system. Via Cav1.1, a t-tubular action potential activates 
the Ca2+ release channel (also called the ryanodine receptor) and the 
Ca2+released from the sarcoplasmic reticulum activates the contractile 
machinery. Hypokalemic PP types 1 and 2 are clinically similar and in both 
responsible channels, the mutations are located exclusively in the  voltage 
sensing S4 segments: those of SCN4A are situated in domain 2 and those of 
Cav1.1 in domains 2 or 4. Functionally, the inactivated state is stabilized in the 
Na+ channel mutants, while the channel availability is reduced for the 
Ca2+channel mutants. It is still unclear how the loss-of-function mutations of 
these two cation channels can produce the long-lasting and pronounced 
membrane depolarization that inactivates the sodium channels and thereby leads 
to the fiber inexcitability8 . 
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Fig .3 Voltage-gated ion channel function in normal and pathological conditions; 
physiologically, Na+ voltage-gated channels switch between three different states 
(closed, open and inactivated) according to time and membrane potential 
variations.When the channels are open, there is an inward Na+ current and a 
compensatory K+ outward current (not represented) responsible for the 
generation and transmission of the action potential. In the case of hyperkalaemic 
periodic paralysis (HyperPP), mutations affecting the tertiary structure of the 
protein reduce the affinity of the fast inactivation particle(corresponding to the 
intracellular protein loops between transmembrane domains III and IV of 
Nav1.4) for his docking site. In these situations, Nav1.4 channels stay 
preferentially in their open, activated state (gain-of-function defect) causing a 
Na+ inward current, a sustained membrane depolarization and the release of K+ 
from muscular cells. By contrast, in the case of hypokalaemic periodic paralysis 
(HypoPP), mutated channels remain closed after membrane depolarization (loss-
of-function defect), causing a lack of action potential initiation/ transmission  
responsible for muscle inexcitability. 4 
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Kir2.1 channels stabilize the resting membrane potential in skeletal and 
cardiac muscle. Reduced Kir2.1 channel function in skeletal muscle may cause 
sustained membrane depolarization, leading to failure of action potential 
propagation and flaccid paralysis12. 
Clinical features and Diagnosis 
The attack frequency varies from daily to yearly and attacks frequently 
lasts for 3 to 4 hours to a day or more and are frequently precipitated by sleep or 
rest after exercise, alcohol or high carbohydrate meal and almost never occur 
during exercise. The limb muscles are more affected than the trunk muscles and 
proximal muscles are more affected than the distal ones.11 Diagnosis is made by 
demonstrating the presence of low potassium during a paralytic attack and by 
excluding other secondary causes of hypokalemia. ECG will show features of 
hypokalemia.  A clinical diagnosis of sporadic periodic paralysis can be made if 
hyperthyroidism and family history of HPP  are both absent13. 
 
Thyrotoxic periodic paralysis 
Epidemiology 
  Incidence of Thyrotoxic periodic paralysis is highest among Asian 
population. Approximately 2% of patients in China and Japan reportedlyhave 
TPP. Despite a higher incidence of thyrotoxicosis in women TPP occurs 
predominantly in men; the male-female ratio is approximately 20:1. Presence of 
Certain HLA antigen subtypes such as HLA-DRw8 , A2, Bw22,Aw19 and B17 
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is suspected to make some of the Asian population susceptible to TPP. TPP 
occurs most commonly in summer and autumn. Increased consumption of sweet 
drinks, outdoor activities and exercise and increased potassium loss in sweat are 
possible explanations for the seasonal pattern14. 
Pathophysiology15 
• Hyperthyroidism results in hyperadrenergic state. β2 adrenergic 
stimulation increases the activity of Na+,k+-ATPase pump.  
• Thyroid hormone per se increases the activity of Na+,k+-ATPase pump.   
• Hyperinsulinemia observed in patients with acute attack of TTP indirectly 
also stimulates Na+,k+-ATPase pump. 
Clinical & Laboratory findings 
Occurs in persons aged 20-40 years in contrast to familial HPP which 
occurs in persons aged less than 20 years15. Nearly half of the patients with TPP 
have no obvious symptoms related to hyperthyroidism during an attack17. 
Patients usually have abnormal thyroid functions, hypokalemia,with a urinary 
potassium-creatinine ratio less than 2meq/mmol. Urinary phosphate excretion is 
reduced remarkably as a result of increased shift of phosphate into the cells . 
Hypercalciuria and hypophosphaturia need to be emphasized in diagnosing 
TPP14. 
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TPP attacks occur only when thyrotoxicosis is present. Attacks can be 
induced by insulin and carbohydrate  administration in hyperthyroid patients 
with a history of TPP, but not in TPP patients who have become euthyroid. 
Paralytic attacks can recur with relapse into a thyrotoxic state, and can be 
induced by exogenous thyroid  hormone.17 
 
Barium poisoning  
 The first cases were referred to as Pa Ping disease, due to an outbreak of 
paralysis in the Pa Ping area of the Szechwan province of China caused by 
ingestion of table salt contaminated by a periodic barium salt. Most of the 
instances of acute toxicity have occurred due to ingestion of barium carbonate 
(rodenticide), food contaminated by barium carbonate (used in error instead of 
potato meal), or carelessness in handling rat poison whereby it is mixed with 
flour and eaten. The fatal dose of barium carbonate is about 0.8 g. However, 
barium doses as low as 0.2–0.5 mg/kg body weight, resulting from barium 
carbonate or chloride ingestion, have been found to produce toxicity in adults. A 
shift of potassium from extracellular to intracellular fluid is the basis of acute 
hypokalaemia in cases of barium carbonate toxicity. The exact mechanism of 
hypokalaemia is not known, however, it may be due to the activation of sodium–
potassium-stimulated ATPase at the cell surface causing potassium entry into the 
cell at the cost of extracellular fluid. Barium is reported to block the potassium 
channels and thereby reduce the potassium efflux from muscles. It also 
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competitively reduces the permeability of the cell membrane to potassium which 
may lead to membrane depolarization. The treatment of barium-induced 
hypokalaemic paralysis has been intravenous potassium administration.The 
potassium reverses the hypokalaemia as well as displacing barium from 
potassium channels, allowing it to be excreted in urine. 6  
 
Renal Tubular Acidosis 
 
Introduction 
 Renal tubular acidosis (RTA) comprises of a group of disorders 
characterized by a low capacity for net acid excretion and persistent 
hyperchloremic metabolic acidosis. 
Physiology 
 The proximal renal tubule is the site of the bulk of solute and water 
reabsorption in the nephron. Approximately 60% of the filtered sodium (Na +) is 
reabsorbed in the proximal segments, along with water, potassium (K+), 
bicarbonate (HCO3−), phosphate, amino acids and low molecular weight 
proteins. In contrast, the distal tubule has a specialized role in the final 
modification of urine concentration and pH. Specialized transporters are 
involved in the regulation of Na+ and K+ reabsorption and H+ secretion.20  
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Fig 4 . Renal potassium handling 5 
 
Classification of RTA 
 
 Based on pathophysiology, RTA has been classified into three types: type 
1 (distal) RTA; type 2 (proximal) RTA; and type 4 RTA  secondary to true or 
apparent hypoaldosteronism. they can be either primary, with or without known 
genetic defects or secondary to other causes. Secondary RTA is more common 
than the primary variety. Renal involvement is reported to occur in up to 67%  of 
patients with primary Sjögren’s syndrome. 21   
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Pathophysiological basis 
 The primary defect in proximal RTA is reduced renal threshold for HCO3- 
, resulting in bicarbonaturia. Renal NaHCO3 losses lead to intravascular volume 
depletion, which in turn activates the renin-angiotensin-aldosterone system. 
Distal Na+ delivery is increased as a result of the impaired proximal reabsorption 
of NaHCO3. Because of the associated hyperaldosteronism and increased distal 
nephron Na+ reabsorption, there is increased K+ secretion. The net result is renal 
potassium wasting and the development of hypokalemia. In the steady state, 
when virtually all the filtered HCO3− is reabsorbed in the proximal and distal 
nephron, renal potassium wasting is less and the degree of hypokalemia tends to 
be mild. Proximal RTA may represent isolated or generalized proximal tubular 
dysfunction, the latter (Fanconi syndrome) characterized by tubular proteinuria 
and aminoaciduria and variable degrees of bicarbonaturia, phosphaturia, Na + 
and K + wasting and glucosuria22. K + wasting is enhanced due to increased distal 
tubular delivery of Na+ and hyperaldosteronism secondary to volume 
contraction. Proximal RTA without Fanconi syndrome may be inherited as 
autosomal dominant and recessive form.  
 The diagnosis of proximal RTA calls for study of other proximal tubular 
functions. Proximal RTA should be suspected in a patient with a normal anion 
gap acidosis and hypokalemia who has an intact ability to acidify the urine to 
below 5.5 while in a steady state.23 Proximal tubular dysfunction, such as 
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euglycemic glycosuria, hypophosphatemia, hypouricemia, and mild proteinuria, 
helps support this diagnosis. The UAG is greater than  zero, indicating the lack 
of increase in net acid excretion. Disorders that are associated with proximal 
RTA and Fanconi syndrome should be  specifically screened for, including 
cystinosis, Lowe's syndrome, galactosemia and Wilson's disease24. 
 
Causes of Type 2 RTA22 
Not associated with Fanconi syndrome 
 Sporadic 
Familial 
 Disorders of Carbonic anhydrase 
  Drugs: Acetazolamide, sulfanilamide, topiramate 
  Carbonic anhydrase II deficiency 
 
Associated with Fanconi syndrome 
Selective(no systemic disease present) 
 Sporadic 
 Familial 
  AR proximal RTA with ocular abnormalities 
  AR proximal RTA with osteopetrosis  and cerebral calcification 
Generalized(systemic disorder present) 
  Genetic disorders 
  Cystinosis 
  Wilson’s disease 
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  Hereditary fructose intolerance 
  Lowe syndrome 
  Metachromatic leukodystrophy 
 Dysproteinemic states 
     Myeloma kidney 
  Light chain deposition disease 
 Primary and Secondary hyperparathyroidism 
 Drugs and toxins 
  Outdated tetracycline 
  Iphosphamide 
  Gentamicin 
  Lead, Cadmium, Mercury 
 Tubulointerstitial disease 
  Post-tansplant rejection 
  Balkan nephropathy 
  Medullary cystic disease 
 Others 
  Bone fibroma 
  Osteopetrosis 
  Paroxysmal Nocturnal Hemoglobinuria 
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Hypokalemic Distal RTA 
 Metabolic acidosis secondary to decreased secretion of H+ ions in the 
absence of marked decrease in the glomerular filtration rate is characteristic of 
distal RTA. Patients with distal RTA are unable to excrete ammonium (NH4+) 
ions in amounts adequate to keep pace with a normal rate of acid production. In 
hypokalemic distal RTA, urine pH cannot reach maximal acidity (i.e., remains 
>5.5) despite systemic acidemia indicating low H+ concentration in the collecting 
duct. Distal RTA can be caused by either impaired H+ secretion (secretory 
defect) or an abnormally permeable distal tubule, resulting in increased backleak 
of normally secreted H+ (gradient defect); it may be genetic or acquired22. In the 
secretory defect, the rate of secretion of H+ is low for the degree of acidosis. 
Ideally, with a rate defect the ability to maximally acidify the urine should be 
retained. However, with a severe rate defect, the time spent in tubule lumen may 
be insufficient for acidification, and there is failure to maximally decrease the 
urine pH. The defect in secretory distal RTA may be secondary to defective 
function of H+ ATPase, H + /K + ATPase, or the Cl - / HCO3− exchanger.  
In distal RTA, the titrable acidity and NH4+ secretion is low resulting in 
systemic acidosis. The development of systemic acidosis tends to diminish net 
proximal fluid reabsorption with an increase in distal delivery, resulting in 
volume contraction and activation of the renin-aldosterone system. Increased 
distal Na+ delivery coupled to increased circulating levels of aldosterone then 
leads to increased renal K+ secretion22. Incomplete distal RTA is a variant or 
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milder form of classic distal RTA, in which there is defective tubular H+  
secretion but plasma HCO3− levels are normal. Daily net acid excretion is 
maintained by enhanced ammoniagenesis. Hypercalciuria and hypocitraturia are 
present, and there is a risk for nephrolithiasis and nephrocalcinosis.25 
 Distal RTA may be a primary disorder, either idiopathic or inherited, but 
it most commonly occurs in association with a systemic disease, of which one of 
the most common is Sjögren's syndrome. Hypergammaglobulinemic states as 
well as drugs and toxins may also cause this disorder. A common cause of 
acquired distal RTA is glue sniffing. Inhalation of toluene from the fumes of 
model glue, spray paint, and paint thinners can give rise to hypokalemic normal 
gap acidosis through multiple mechanisms. First, toluene inhibits collecting duct 
proton secretion. Second, metabolism of toluene produces the organic acids 
hippuric and benzoic acid. These are buffered by sodium bicarbonate, resulting 
in metabolic acidosis and the production of sodium hippurate and sodium 
benzoate. If plasma volume is normal, these salts are rapidly excreted in the 
urine, and a non–anion gap metabolic acidosis develops. If plasma volume is 
decreased, urinary excretion is limited, they accumulate, and an anion gap 
metabolic acidosis develops.22 
Causes of Type 1 RTA 22 
 
Primary 
 Idiopathic 
 Familial 
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Secondary 
 Autoimmune disorders 
  Hypergammaglobulinemia 
  Sjogren’s syndrome 
  Primary biliary cirrhosis 
 SLE 
          Genetic diseases 
 AD type 1 RTA  
 AR  
         Drugs and toxins 
 Amphoterecin B 
 Toluene 
        Disorders with nephocalcinosis 
 Hyperparathyroidism 
 Vit D intoxication 
 Idiopathic hypercalciuria 
      Tubulointerstitial diseases 
 Obstructive uropathy 
 Renal transplantation 
 
In patients with minimal disturbances in blood pH and plasma HCO3− 
concentration, a test of urinary acidification is required. Traditionally, such a test 
involved oral NH4Cl administration to induce metabolic acidosis with 
assessment of the renal response by serial measurement of urine pH. Many 
patients poorly tolerate NH4Cl ingestion because of gastric irritation, nausea, and 
vomiting. An alternative way to test the capacity for distal acidification is to 
administer furosemide and the mineralocorticoid fludrocortisone 
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simultaneously.26 The combination of both increased distal Na+ delivery and 
mineralocorticoid effect will stimulate distal H+ secretion by both an increase in 
the luminal electronegativity and a direct stimulatory on H+ secretion. Normal 
subjects will lower urine pH to values below 5.5 with either maneuver. 
 
Urine pH & Ammonium chloride loading test 27 
 Urine pH is useful for assessing the overall integrity of distal urinary 
acidification. In the presence of systemic acidosis, present spontaneously or 
induced by ammonium chloride load, the urine pH is normally <5.5. Presence of 
urine pH >5.5 during metabolic acidosis suggests defective distal secretion of 
H+. It should however be appreciated that the urine pH measures the 
concentration of free H+ in the urine. This constitutes <1% of the total amount of 
H+ secreted in the distal nephron during systemic acidosis, since most protons 
are excreted as NH4+ or titrable acidity. Urine pH values < 5.5 are seen in 
subjects with proximal RTA during systemic acidosis and low filtered load 
(plasma HCO3- <15 mEq/L), or in patients with selective aldosterone deficiency.  
If systemic acidosis is absent, an oral ammonium chloride challenge (0.1 
g/Kg) might be given, followed by the measurement of urine pH every hr for the 
next 28 hr. If the plasma total CO2 content falls by 3-5 mEq/L, the urine pH 
should fall to <5.5. Another protocol involves giving the same dose of 
ammonium chloride daily for 3-5 days, followed by measurement of urine pH 
and urinary NH4+ excretion; the latter should  increase 35 times the baseline by 
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the third day of induced acidosis. In patients with liver disease, calcium chloride 
may be used as an acidifying agent at a dose of 2 mEq/Kg. The pH is measured 
electrometrically on fresh voided, early morning urine specimen. The use of 
dipstick is not recommended. Urine kept standing is likely to get contaminated 
or infected with urea-splitting organisms, resulting in high urine pH. The urine 
pH must be evaluated in conjunction with the urinary NH4+ content to assess the 
acidification process. Low urine pH does not always imply an intact urinary 
acidification mechanism, if excretion of NH4+ is low, as might occur in proximal 
RTA. 
 
Bartter Syndrome 
 
Introduction 
 Bartter syndrome is a heterogeneous group of disorders characterized by 
primary renal tubular disorders associated with hypokalemic metabolic alkalosis 
and hyperreninemia with normotension. Bartter syndrome is rare and is 
manifested in childhood or in the perinatal period with severe hypokalemia, 
metabolic alkalosis, and low-normal blood pressure, all of which are caused by 
tubular wasting of Na+ and Cl−. In contrast, Gitelman's syndrome is mostly a 
disorder of adults, and hypomagnesemia is a defining feature22. 
  Bartter's syndrome may result from mutations affecting any of the four 
ion transport proteins in the TAL. The proteins affected include the apical loop-
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diuretic sensitive sodium-potassium-chloride co-transporter NKCC2 (type 1), the 
apical potassium channel ROMK (type 2), and the basolateral chloride channel 
ClC-Kb (type 3). Bartter type 4 results from mutations in barttin, an essential 
subunit of ClC-Ka and ClC-Kb that enables transport of the chloride channels to 
the cell surface. The TAL transporters function in an integrated manner to 
maintain both the electrical potential difference and sodium gradient between the 
lumen and the cell. Loss of the lumen-positive electrical transport potential that 
normally drives the paracellular reabsorption of sodium, calcium, and 
magnesium causes NaCl wasting, hypercalciuria, and mild hypomagnesemia. 
The clinical syndrome mimics a state induced by chronic ingestion of a loop 
diuretic. Bartter syndrome from mutations in NKCC2, ROMK, or barttin has a 
more severe phenotype than that caused by mutations of ClC-Kb. The more 
severe phenotype typically presents in the perinatal period and is called antenatal 
Bartter syndrome. The milder variety is called classic Bartter syndrome( Type 
3)22. 
 In some cases prenatal diagnosis is possible in the presence of important 
signs and symptoms such as polyhydramnios, polyuria and dehydration. In other 
patients diagnosis is usually made during childhood due to the appearance of 
tetanic crises or growth failure. Other patients are  completely asymptomatic and 
the diagnosis is made in adolescent or adult life following blood tests prescribed 
for intercurrent diseases. 
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Bartter's syndrome –Types 23 
Type Inheritance Locus Gene Protein  Renal Abnormalities 
  Type 1  AR 15q15 SLC12A1 NKCC2 Salt wasting; hypokalemia 
  Type 2  AR 11q24 KCNJ1  ROMK Salt wasting; hypokalemia
  Type 3   AR 1p36 ClCNKb  CLCNKB Salt wasting; hypokalemia
  Type 4   AR 1p31 BSND  Barttin Salt wasting; hypokalemia
 
 
Fig 6 : Bartter’s Syndrome 23 
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Neonatal Bartter’s syndrome 
 Features of neonatal Bartter’s syndrome include marked polyhydramnios, 
premature delivery, weight loss, lethargy, failure to thrive and polyuria28. An 
important biochemical abnormality of the amniotic fluid is consistently elevated 
chloride levels. In the first week of life, laboratory investigation shows a 
metabolic alkalosis associated with hypokalaemia. The urine has low specific 
gravity with very high sodium, chloride and calcium levels, while potassium is 
normal. However, after 1–3 weeks, the level of potassium in the urine rises to 
considerably above normal, with relatively less sodium than in the first week of 
life. Prostaglandin levels are high, both in blood and in urine29. 
 
Molecular basis 
 A genetic heterogeneity was clearly demonstrated by Simon et al in those 
with the antenatal (hypercalciuric) variant of Bartter syndrome, also termed 
hyper prostaglandin E syndrome . The hypothesis that a loss of function of the 
absorptive form of the bumetanide-sensitive Na-K-2Cl reabsorption of this 
segment could produce the features of these patients was proved by Simon et al  
who demonstrated that the human NKCC2 gene maps on chromosome 15q15-
21, is encoded by 26 exons, like TSC, and is made up of 1,099 amino acids. The 
same group subsequently showed that mutations in another gene encoding the 
inwardly-rectifying renal potassium channel (ROMK) may also cause the 
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hypercalciuric variant of Bartter syndrome. This last gene was mapped on 
chromosome 11q21-2530,31.  
 Defects in either Na+-K+-2CI- cotransport or K+ channels will result in 
malreabsorption of Na+, K+, Cl-, and Ca2+ in the thick ascending limb of loop of 
Henle primarily, with subsequent reabsorption of H2O in the descending loop of 
Henle. The result of such a defect will be the delivery of large volumes of urine 
with a high content of Na+, K+, Cl-, and Ca2+ to the distal tubule. In the distal 
tubule, part of the delivered Na+ will be reabsorbed in exchange for intracellular 
K+. By this action, partial but incomplete concentration of the intraluminal fluid 
will be accomplished, while more potassium wasting becomes evident. 
However, this impaired sodium absorption in the thick ascending limb of loop of 
Henle will result in increased levels of prostaglandin E2. This interrelation has 
been documented in normal individuals using loop diuretics32. 
 Increased prostaglandin E2 levels will exacerbate the primary defect of chloride 
transport in the thick ascending loop of Henle which will28: 
  (i) stimulate the renin-angiotensin- aldosterone axis causing hypokalemia 
 due to increased aldosterone activity; 
 (ii) impede ROMK channel activity and hence decrease NaCl transport; 
 and 
 (iii) impede H2O reabsorption in the collecting ducts due to a secondary 
 effect on vasopressin activity, resulting in hyposthenuria. 
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Classic Bartter Syndrome 
 
(Bartter syndrome type 3) 
 Classical Bartter syndrome is characterized by early childhood onset. The 
patients fail to thrive but have no tetany. Symptoms may include polyuria, 
polydipsia, vomiting, constipation, salt craving, and a tendency to dehydration. 
Failure to thrive and growth retardation follows if treatment is not initiated. 
However the normal adult height usually achieved by untreated individuals is 
due to a delayed adolescent growth spurt. They have hypokalaemic metabolic 
alkalosis and their urinary Ca2+ is either normal or slightly elevated, with the 
urine concentration being almost normal. There are reports of Bartter syndrome 
presenting with hypokalemic periodic paralysis. 
Molecular Basis 
 The biochemical abnormalities of classical Bartter syndrome are all 
suggestive of a defect related to Cl- transport in the medullary thick ascending 
loop of Henle. However, the precise pathway involved is not yet clear. The 
familial cases of classical Bartter syndrome are inherited as an autosomal 
recessive entity. A group of patients with this phenotype all had either a large 
deletion or nonsense, missense, or splice mutations of the gene (CIC-Kb, 
chromosome 1p36) encoding the renal chloride channels of the basolateral cell 
membrane. 
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 However, in some patients with classical Bartter syndrome, no 
abnormality in this gene could be identified. It has therefore been suggested that 
NaCl transport in the ascending loop of Henle (and the relevant gene/s) may also 
be involved28. 
 
Gitelman’s syndrome 
 Gitelman's syndrome is due to mutations in the thiazide-sensitive Na-Cl 
co-transporter (NCCT) in the DCT. Defects in NCCT in Gitelman's syndrome 
impair sodium and chloride reabsorption in the DCT and, thus, resemble the 
effects of thiazide diuretics. 
 Onset is late, usually after the age of 20 years. Patients present with 
fatigue, muscle weakness and recurrent episodes of tetany33 Biochemically, there 
is metabolic alkalosis, (serum bicarbonate >29 meq/1) profound hypokalaemia, 
(serum potassium <3 meq/l; normal >3.5 meq/1) hypomagnesaemia (serum 
magnesium <0.5 meq/l; normal 0.8–1.0 meq/1) and hypocalciuria, (urinary 
calcium <2 mg/kg per day).35 Urinary concentrating ability in this disease is 
mildly impaired. 
Pathophysiology 
 The basic pathology in this disease is an impaired Na-Cl cotransporter in 
the distal nephron. Distal tubule and collecting duct together reabsorb about 12% 
of the filtered Na+. The early distal tubule, also called the cortical diluting 
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segment, is the site of absorption of NaCl by Na+-Cl- cotransport (NCCT) and is 
the site of action of thiazide diuretics. A similar biochemical abnormality can be 
seen in long-term use of thiazide diuretics in an otherwise normal individual. 
NaCl wasting in this part of the distal nephron will lead to mild hypovolemia, 
and stimulation of the renin- angiotensin axis. Simon et al. showed that there is a 
complete linkage of Gitelman’s syndrome to the locus encoding the renal 
thiazide sensitive Na+- Cl- cotransporter on chromosome 16q13, with an 
autosomal recessive pattern and a 99% penetrance. Mutant alleles in this disease 
have been reported by Simon and others. 28 
The late distal tubule and collecting duct have two kinds of cells, each 
with special feature and function. Principal cells reabsorb Na+ and H2O and 
secrete K+ . Aldosterone acts on principal cells to increase Na+ reabsorption and 
increase K+ secretion. Intercalated cells secrete H+ ions in exchange for 
reabsorption of K+ ions. Aldosterone increases H+ ion secretion by intercalated 
cells. Impairment of Na+-Cl- cotransport in the early part of the distal tubule 
results in excessive amounts of Na+ ion in the late distal tubule. Maximal 
reabsorption of Na+ and H2O and maximal secretion of K+ ion by the principal 
cells takes place in this segment.At the same time, H+ is excreted by intercalated 
cells and this, together with impaired Cl- reabsorption in the early distal tubule, 
results in metabolic alkalosis. 
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 The high intake of Ca2+ in distal tubule and hence hypocalciuria is 
probably due  to  
(a) decreased apical Na+ uptake driving basolateral Na+/ Ca2+ exchange 
with subsequent increase of Ca2+ uptake at the apical membrane level and  
(b) decreased intracellular Cl- content increasing the polarity of the apical 
cell membrane, which stimulates Ca2+uptake.34 
 Hypomagnesaemia in Gitleman syndrome is perhaps due to magnesium 
wasting in distal convoluted tubules of the nephron due to inhibition of Mg2+ 
uptake in the presence of hypokalaemia.35 It has also been suggested that the 
metabolic alkalosis may be an important cause of hypomagnesaemia by 
increasing the resistance of distal tubular cells to Mg2+ uptake.40 With low Mg2+ 
levels in the blood, magnesium wasting has been observed in patients with 
Gitelman’s syndrome, indicating a too-low renal Mg2+ threshold. 
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Fig 7 . Gitelman’s syndrome 23 
 
Liddle’s syndrome 
 Liddle syndrome is an autosomal dominant syndrome of hypertension and 
variable degrees of hypokalemic metabolic alkalosis. The patients resemble 
those with primary hyperaldosteronism, but levels of mineralocorticoid 
hormones are not increased. Renin and aldosterone are suppressed, and there is 
no response to spironolactone. However, triamterene and amiloride, aldosterone-
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independent inhibitors of distal Na+ transport, correct hypertension, renal K+ 
loss, and hypokalemia.52 
Pathophysiology 
 Liddle syndrome is related to mutations of the β or γ subunit of the 
collecting duct sodium channel ENaC. In Liddle syndrome, the mutated ENaC 
protein cannot be recognized by NEDD4, a ubiquitin ligase protein; hence, the 
channels remain in the cell membrane for prolonged periods. This action results in 
enhanced sodium reabsorption, hypertension, and hypokalemic alkalosis.53 
 
Primary Hyperaldosteronism 
 Primary hyperaldosteronism accounted for about 42% of patients with 
periodic paralysis in a  case series from south India36. It is suspected in a patient 
with hypokalemic periodic paralysis if there is a combination of metabolic 
alkalosis and hypertension. It is then confirmed by imaging studies and 
biochemical investigations. Periodic paralysis as a presentation of primary  
hyperaldosteronism is commonly reported among the oriental races. In a series 
of 50 patients with primary hyperaldosteronism from Taiwan, 42% presented 
with periodic paralysis, although all 50 had hypokalaemia37.  
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Approach to the patient with hypokalemic palaysis  
 
 Failure to distinguish HPP from non-HPP may lead to overly aggressive 
treatment of an apparent potassium deficit, with rebound hyperkalemia on 
recovery. In retrospective studies by Manoukain and Lin and colleagues, 
rebound hyperkalemia occurred in 30% to 42% of patients with HPP, especially 
if more than 90 mmol of potassium chloride was given within 24 hours14. Hence 
diagnosis of the etiology is important.  
Diagnosis for the cause of hypokalemia is based mainly on determining if there 
is a net loss of K+ or only a transcellular shift. 
Diagnostic tests 
 Serum K+ 
 Blood urea nitrogen, 
 Serum creatinine 
 Acid-base status 
 Urinary Potassium 
 Transtubular potassium concentration gradient (TTKG) and 
 Urinary Potassium creatinine ratio (K+/C) 
 Thyroid function tests – if features suggestive of a transcellular shift 
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 Three urinary indices of renal response to hypokalemia can be easily 
measured: spot urine potassium concentration, TTKG, and Urine potassium-
creatinine ratio.2 
The spot urine potassium concentration is lower in the HPP than the non-
HPP  (<15-20 mmol/L); however, there can overlapping values because polyuria 
is common in patients with hypokalemia . The polyuria may be due to thirst or 
defective renal concentration in patients with chronic hypokalemia; this leads to 
a low value for the urine potassium  concentration even if significant renal 
potassium wasting is present. 
The TTKG is a semiquantitative index for events in the lumen of the 
cortical collecting ducts, because it adjusts for the plasma potassium 
concentration and for  water reabsorption in the medullary collecting ducts.11,18 
Although calculating the TTKG is a reliable way to distinguish between HPP 
and non-HPP, a TTKG is invalid if theUosm is lower than the Posm in a patient.  
The potassium- creatinine ratio is independent of the Uosm. Urine  
potassium-creatinine ratio less than 2.5 mmol/mmol and TTKGs less than 3.0 in 
hyperosmolar urine are reliable cutoff values to differentiate between patients 
with HPP and non-HPP.2 
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 Fig 8: Appoach to a patient with hypokalemia and paralysis 2 
 
Clinical features suggestive of a transcellular shift :  
1. Familial hypokalaemic PP 
 Caucasian 
 Family history +ve 
 Onset in 1st/2nd decade 
 Precipitated by meals high in carbohydrates/Na+ or rest/sleep after 
exercise 
 Normal acid-base balance , Normal Blood pressure 
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 Low K+ excretion 
2. Thyrotoxic PP 
 Asian 
 Family history –ve 
 Onset in 2nd/4th decade 
 Sign/symptoms of hyperthyroidism 
 Predominantly males 
 Normal acid-base balance, Normal Blood pressure 
 Low K+ excretion 
 
Hypokalemia secondary to K+ loss 
 Hypokalemia secondary to K+ loss can be differentiated based on clinical 
features like Blood pressure and also history suggestive of the aetiologies 
mentioned below and also by looking at the acid base status and urinary K+ loss 
in the patient. 
Determination of the urinary K+ concentration alone might be misleading, 
because K+ depletion can cause polyuria and a relatively low K+ 
concentration(<20mmol/l) could still represent substantial urinary K+ loss. The 
TTKG provides a better way to evaluate the excretory process. 13 
The transtubular K+ concentration ([K+]) gradient (TTKG) is calculated using the 
following formula: 
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 TTKG = [urine K+/plasma K+] / [urine osmolality/plasma osmolality] 
 
To differentiate individual causes of renal K+  wasting the following 
investigations may be done 
 Urinary pH 
 Ammonium loading test 
 Serum and urinary electrolytes – Na , K, Cl, Ca, Phosphate,Mg 
 Alkaline phosphatase 
 Creatine kinase 
 24 h urinary  calcium, inorganic phosphate, and creatinine 
 Urinary aminoacids 
 Seum aldosterone and renin  levels 
 
Management 
Treatment of Periodic paralyses 
 Body potassium stores are normal in patients with FPP and TPP. Hence 
the aim of potassium supplementation is to normalize the plasma potassium 
instead of  repairing the potassium deficit.  Initial treatment of acute episodes of 
FPP is oral potassium supplementation (0.2-0.4mmol/kg)  every 15 to 30 
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minutes depending on potassium levels, ECG changes and muscle strength. 
Intravenous therapy is necessary when the patients are unable to swallow or 
vomiting. Prophylaxis against recurrent episodes has been successful with wide 
variety of drugs like acetazolamide (125-1000mg/day), spiranolactone (25-100 
mg/day) and triamterine (25-100 mg/day).6 
In a study conducted by Lin et al, they found that the average recovery 
time is two times shorter in patients with TPP treated with intravenous potassium 
chloride supplementation at a rate of 10meq/h than in controls. However 
rebound hyperkalemia occurred in 70% of patients treated with potassium 
chloride. Patients receiving 50 mmols or less rarely developed hyperkalemia. It 
appears that low doses may be efficacious while substantially reducing the risk 
of hyperkalemia8. Oral β blockers (propranolol 3-4mg/kg) appear to be effective 
with out causing rebound hyperkalemia.  
 Propranolol is effective in preventing recurrent attacks by suppressing the 
activity of Na+,k+-ATPase pump15. Regular potassium chloride supplementation 
is futile because potassium levels are normal during the inter attack period. 
Acetazolamide can precipitate recurrent attacks of TPP and should not be used8. 
Management of Hypokalemia secondary  to potassium loss 
 Any depletion of potassium – renal or non renal has to be corrected by 
replacing the lost potassium and also the underlying cause corrected to prevent 
futher loss. 
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Treatment of Proximal RTA 
 Children should treated to prevent growth retardation. Alkali must be 
given in large amounts daily, 5 to 15 mmol/kg/day, because bicarbonate is 
rapidly excreted in urine. A thiazide diuretic can be used in conjunction with low 
salt to reduce the amount of bicarbonate required. Potassium requirements 
increase during alkali therapy due to increased renal loss of potassium from 
bicarbonaturia38. 
Adults with proximal RTA are frequently not treated as aggressively as children 
are because of the lack of systemic metabolic abnormalities or bone disease.22 
Treatment of Distal RTA 
 Distal RTA is treated with potassium replacement and alkali solution. The 
dose is 0.5 to 2 mmol/kg/day with an aim to keep the bicarbonate level above 
18mEq/L. Alkali supplementation is  either as sodium bicarbonate or Shohl’s 
solution38 . It is a mixture of 98 gm of hydrated sodium citrate and 140 gm of 
citric acid dissolved in 1000ml of distilled water. Potassium citrate can be  used 
instead of sodium citrate if hypokalemia correction is required  . In patients with  
osteomalacia, calcium and vitamin D form integral part of therapy in addition to 
correction of acidosis . 
Treatment of Bartter syndrome 
 The therapeutic management of Bartter syndrome is composed of two 
major aspects:  
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(i) replacement therapy and (ii) use of drugs. 
Dietary intake of sodium and potassium should be liberal. Potassium 
supplements are usually required.. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are useful, particularly in patients with antenatal Bartter’s syndrome, 
since they reduce prostaglandin production. Indomethacin (1 to 3 mg/kg per 24 
hours) 39 or ibuprofen is commonly used for both all types and initial response in 
good in both types although better in antenatal Bartter. 
If not treated, patients may succumb to episodes of dehydration, electrolyte 
disturbance, or intercurrent infection. With appropriate therapy, most children 
improve clinically and show catch-up growth; pubertal and mental developments 
are usually normal. Lifelong therapy is needed. Chronic tubulointerstitial 
nephropathy due to persistent hypokalemia, hypercalciuria, and nephrocalcinosis 
may lead to progressive decline in renal function22. 
 
Treatment of Gitelman’s syndrome 
 Replacement therapy is the main treatment for Gitelman’s syndrome, 
which means magnesium supplementation throughout life. Administration of 
magnesium in the form of MgCl2 partially corrects hypomagnesaemia and hence 
prevents the appearance of tetany as well as compensating for ongoing chloride 
losses by the kidney.40 Acid-base status, urinary Ca excretion and renin-
angiotensin axis are all corrected. Also correction of hypokalemia may 
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occasionally require the addition of potassium salts and/or anti-aldosterone drugs 
such as spironolactone or amiloride.41 
 
Treatment of Liddle’s syndrome 
 Therapy consists of sodium restriction and K+ supplements. Triamterene 
directly inhibits apical Na+ channels, resulting in increased urinary Na+ and 
decreased K+ excretion and resolution of hypertension. Amiloride also normalizes 
the blood pressure and K+ levels. However, most patients continue to have growth 
retardation. Because the pathogenetic disorder is not correctable with age, lifelong 
therapy is required.5 
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MATERIALS AND METHODS 
 
Study population 
 Patients admitted in medical and general wards of Rajiv Gandhi 
Government General Hospital, Chennai-3, from January 2009- March 2011 with 
acute onset of flaccid weakness and documented serum potassium of < 3.5 
mEq/l during the episode were included in the study. Patients with renal failure 
(serum creatinine >1.5 mg/dl) were excluded. 
 
Evaluation 
 Clinical data collected included Age, Sex, ethnic origin, history regarding 
the evolution of the symptoms, precipitating factors like, high carbohydrate 
intake in the preceding 24 Hrs, alcohol consumption and treatment taken. Any 
history of similar disease in the family was enquired about, and reports of 
weakness, thyroid disease, diarrhea, vomiting, hypertension, bone pain, 
fractures, dry mouth, dry eyes, and kidney disease were recorded. Intake of 
drugs like diuretics, β2 agonists, decongestants, insulin, laxatives and 
antipsychotics were noted. Excessive caffeine and herbal drugs usage were 
excluded. 
  The examination included anthropometry, pulse, blood pressure, anemia, 
thyroid status. Complete neurological examination was performed. Schirmer’s 
test was performed in selected patients.  
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Laboratory investigations 
All patients underwent:  
 Routine urine analysis  
 Haemogram, 
 Blood urea, serum creatinine, serum electrolytes 
 Serum calcium, inorganic phosphorus  
 Serum magnesium 
 Serum albumin,globulin, alkaline phosphatase, creatine kinase 
 Spot urine potassium, urine chloride 
 Spot urine  potassium, creatinine ratio 
 Arterial blood gas analysis 
 Electrocardiogram 
 Thyroid Function Tests 
 Ultrasonogram Abdomen. 
 Early morning  urinary pH 
Patients with urinary K+ loss and hyperchloraemic metabolic acidosis with 
normal anion gap underwent: 
 Lip biopsy 
 SSA,SSB antibody 
 ANA  
 Urinary aminoacids.  
 Urine Bence Jones Protein, serum electrophoresis. 
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Patients with urinary K+ loss and metabolic alkalosis underwent: 
 24 hrs urinary calcium 
Patients with Urinary K+ loss with normal acid base status underwent an 
ammonium chloride loading test (0.1 g/kg). TTKG was done when there was 
doubt in diagnosis of hypokalemia due to transcellular shifts or due to renal loss.  
 Serum aldosterone, plasma renin levels, and CT scan of the abdomen was 
done in patients presenting with hypertension, hypokalemia and alkalosis to rule 
out primary hyperaldosteronism. 
 
Statistical analysis 
   All data are expressed as mean ± SD. Differences in group means were 
compared using one-way analysis of variance (ANOVA). Differences in 
categorical variables were compared using Fisher’s exact test. The difference 
was considered significant if  p-value was > 0.05. Data was analyzed using SPSS 
(V: 17) software. 
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Diagnostic approach in a patient with Hypokalemic Paralysis (Lin 
2001)14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypokalemia and paralysis
Low K+ excretion (U K+/Cr <2.5)2and 
normal acid‐ base 
High K+ excretion(U K+/Cr 
>2.5)2and abnormal acid‐ base 
Hyperthyroidism ?
YES  NO 
Metabolic 
alkalosis 
Metabolic 
acidosis 
NO 
High K+ excretion(U K+/Cr 
>2.5 and normal acid‐ base 
YES 
Family History? 
Hypertension
YES  NO
Urinary 
Acidification test 
TP
FP SP
RTA 
DIARRHOEA 
Primary aldosteronism
Liddle’s syndrome 
GS,BS, 
Diuretics 
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RESULTS AND OBSERVATION 
 This study was conducted between January 2009 and March 2011.There 
were 47 patients with a mean age of 32.04 years (Range 18- 50 Years). The M:F 
ratio was 28:19. 
Age Distribution 
Age  No %
<25  4 9%
25‐34  20 43%
35‐44  12 25%
>45  11 23%
Total  47 100%
 
 Hypokalemic paralysis is grouped based on acid-base status into three 
main groups as shown below. 
Groups based on Acid-base status 
No %
Normal Acid‐base  24 51%
Metabolic Acidosis  16 34%
Metabolic Alkalosis  7 15%
Total  47 100%
 
 Out of 47 patients 24(51%) had normal acid base balance, 16 patients 
(34%) had metabolic acidosis, 6 patients (15%) had metabolic alkalosis. 
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Sub groups of Hypokalemic paralysis 
Sub groups   NO %
SPP  20 43%
TPP  4 9%
d RTA  15 31%
p RTA  1 2%
GITELMAN’S SYNDROME  6 13%
LIDDLE’S SYNDROME  1 2%
 
SPP  : Sporadic periodic paralysis 
TPP  : Thyrotoxic periodic paralysis 
d RTA  : Distal Renal Tubular Acidosis 
p RTA  : Proximal Renal Tubular Acidosis 
 
 Of the 24 patients with normal acid base balance none had evidence of 
renal potassium loss (Urine potassium creatinine ratio <2.5), 4(9%) patients in 
this group had biochemical evidence of thyrotoxicosis and were diagnosed as 
Thyrotoxic periodic paralysis (TPP), and 20(43%) patients who had normal 
thyroid profile and negative family history of periodic paralysis were diagnosed 
as Sporadic periodic paralysis (SPP).  
 Of the 16 patients who had metabolic acidosis, all of them had evidence 
of renal potassium loss. One patient had features of generalized proximal tubular 
dysfunction and urine pH was < 5.5 during acidemia and was diagnosed as 
proximal renal tubular acidosis (p RTA), fifteen patients (31%) had urine         
pH > 5.5 during acidemia and were diagnosed distal renal tubular acidosis         
(d RTA). 
 Seven patients had metabolic alkalosis with renal potassium wasting. 
Diuretic use was excluded by careful scrutiny. Of them 6 (13%) were diagnosed 
to have Gitelman’s syndrome since they had hypocalciuria and 
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hypomagnesemia. One patient had hypertension, low plasma renin activity was 
diagnosed Liddle’s syndrome. 
 Age distribution, gender distribution, mean serum potassium, bicarbonate, 
pH,  serum chloride, urinary K+ , urinary K+/Cr ratio, Urinary Cl- ,   and other 
clinical characteristics are shown in the table.     
Comparing the groups 
SPP TPP d RTA p RTA GS LIDDLE P* 
 
No. of Pts 20 4 15 1 6 1  
 
M:F 15:5 3:1 4:11 0:1 5:1 1:0  
 
Age of onset (yrs) 24.6±5.7 43±8.8 36.8±7.3 50 34.67±3.1 32 
 
<0.01 
Duration of illness 
(mo) 22.7±5.07 6.5±4.95 15.4±12 24 37.5±6.3 3 
 
<0.01 
 
No. of episodes 2.9±2 1.5±0.5 3.3±1.7 3 1.5±.57 3 <0.01 
 
Serum K+(mmols/l) 2.47±0.47 2.8±0.34 2.52±0.49 2.6 2.63±0.43 1.8 NS 
 
Serum Cl-(mmols/l) 105±13.5 105±5.3 112±6.9 102 97.83±5.8 103 0.042 
 
Urine K+ (mmols/l) 11.44±2.3 14.75±1.9 28.22±6.7 23 30.91±7 28 <0.01
 
U K+/Cr 1.73±0.36 2.07±0.29 4.35±0.8 3.9 5.5±1.3 5.2 <0.01 
 
Time to Improve(hr) 22.7±5.07 23.75±4.4 31.3±6.2 24 37.5±6.3 12 <0.01 
 
Resp paralysis 3 0 2 0 0 0  
 
Recurrence 4 0 0 0 1 0  
KCl requirement for 
recovery mmols 58±23 47.5±20.6 101.3±18.8 80 90±17.8 50 
 
<0.01 
Rebound 
Hyperkalemia 2 1 0 0 0 0 
 
 
 
*One-way Analysis of Variance (ANOVA)   with  Bonferroni Multiple Comparisons Test. (Liddle’s 
syndrome and  p RTA excluded)  
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 There is a statistically significant difference in the mean age of onset, the 
lowest being SPP group followed by Gitelman’s syndrome group, d RTA, and 
then by TPP. Serum chloride is highest in d RTA and lowest in Gitelman’s 
syndrome group. Highest level of renal K+ loss is seen in Gitelman’s syndrome 
followed by d RTA whereas it is normal in SPP and TPP. 
 HPP (SPP and TPP) required lower potassium chloride supplementation. 
Rebound Hyperkalemia (serum K+ >5 mEq/L) after recovery occurred in 2 
patients in SPP group and 1 patient in TPP. None of the secondary HP patients 
had rebound hyperkalemia. 
Characteristics of patients with Gitelman's syndrome 
S.No Weight Kg 
Age of onset 
Yrs Sex Tetany 
Spot URINE Cl- 
mmol/l 
24 U Ca2+ 
mg/day 
sr Ca2+ 
mg/dl 
sr Mg2+
mg/dl 
1 62 35 M Neg 167 110 8.9 1.6 
2 71 36 M Neg 116 127.5 8.9 1.2 
3 54 37 M Pos 52 105 8.5 0.9 
4 61 32 M Pos 76 123 7.8 0.87 
5 64 30 M Neg 121 109 9.1 1.4 
6 51 38 F Neg 56 103 9 1.5 
 
 All the patients with Gitelman’s syndrome had increased urinary chloride, 
hypocalciuria and hypomagnesemia. One patient with Gitelman’s syndrome had 
hypocalcemia and 2 patients had tetany. 
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Characteristics of Sjogren’s syndrome patients 
S.No 
Age of 
onset Sex 
Ocular/oral 
symptoms Schirmer’s
SSA 
& 
SSB 
Lip 
Bx 
 
Nephrocalcinosis
1 41 F Pos Pos Pos Pos 
2 48 F Pos Pos Pos Neg 
3 47 M Pos Pos Pos Neg 
4 30 F Neg Pos Pos Pos Neg 
5 36 F Pos Pos Pos Pos Pos 
6 40 F Pos Pos Pos Neg 
7 50 F Pos Neg Pos Neg 
 
 Sixteen patients had renal tubular acidosis out of which 7 had Sjogren’s 
syndrome. Out of seven patients of Sjogren’s syndrome, 1 patient had p RTA and 
six had d RTA. All but one patient had xerostomia and xerophthalmia.  
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DISCUSSION 
 In this study in a South Indian population there were 47 patients  who 
fulfilled the inclusion criteria  of whom 24(51%) had HPP with potassium shifts, 
out of which 20(43%) had sporadic periodic paralysis (SPP) and 4 (9%) had non 
familial Thyrotoxic periodic paralysis. Twenty three patients (49%) had non- 
HPP (due to potassium deficit), out of which 16 (33%) had renal tubular acidosis 
(15 d RTA and 1 p RTA), 6 (13%) had Gitelman’s syndrome and one patient had 
Liddle’s syndrome. 
Cause of HP in various studies 
n 
FPP 
n (%) 
SPP 
n (%) 
TPP 
n (%) 
d RTA 
n (%) 
p RTA 
n (%) 
GS 
n (%) 
PA 
n (%) Liddle Others 
Lin SH et al 
200114 97 2(2) 29(30) 39(40) 6(6) 0 6(6) 6(6) 0  
Lin SH et al  
20042 43 1(2) 9(21) 20(47) 5(12) 1(2) 4(9) 1(2) 0 2(4) 
Rao et al1 31 0 2(6) 2(6) 13(42) 0 1(3) 13(42) 0  
Maurya et al43 30 0 17(57) 5(17) 3(10) 1(3) 4(13) 0 0  
Phakdeekitcharoen 
et al42 34 5 (15) 10 (29) 11 (32) 8 (24) 0 0 0 0  
Our study 47 0 20(43) 4(9) 15(31) 1(2) 6(13) 0 1(2) 
 
 In a large series of 97 patients in Taiwan in 2001, Lin SH et al reported 
TPP in 39 (40%), SPP in 29 (30%), Bartter’s/Gitelman’s in 6 (6%), d RTA in 6 
(6%), and Primary Hyperaldosteronism (PH) in 6 (6%). Overall, 66 patients 
(68%) accounted for secondary causes.14   
 In another series reported by the same authors in 2004, out of 43 patients 
9 (21%) had SPP, 20 (47%) had TPP, 6 (13%) had RTA, 4 (9%) had Gitelman’s 
55 
 
syndrome and 1 (2%) had Primary Hyperaldosteronism. Secondary causes 
accounted for 33 cases (76%).2 
 Rao et al published a series of 31 cases from South India, 2 each had SPP 
and TPP, 13 (42%) had d RTA, 1 (3%) had Gitelman’s syndrome and 13 (42%) 
had Primary Hyperaldosteronism.1 
 In a series by Phakdeekitcharoen et al from Thailand of the 34 patients, 
11 (32%), 8 (24%) and 15 (44%) had TPP, d RTA, SPP respectively.42 
 In another study from North India, Maurya et al reported HP in 30 
patients, 17 (56.7%) had primary idiopathic hypokalemic paralysis, 5 (16.7%) 
had TPP, 4 (13.3%) had RTA and 4 (13.3%) had Gitelman’s syndrome.43 
 In most Asian studies TPP is observed as the most common cause of HP, 
18,44 whereas in Caucasians, FPP is more common.45  In our study and the  study 
by Maurya et al, SPP is the commonest group and no FPP is reported. 43 In the  
study by Rao et al, HP due to Primary Hyperaldosteronism (PH) and d RTA are 
the most common causes.1 None of our patients had Primary Hyperaldosteronism 
(PH).  The difference in etiology of HP in our study and Rao et al’s study may 
be due to difference in study setting. Our study was conducted in a tertiary 
nephrology practice, where as Rao et al’s study was undertaken in a tertiary 
endocrinology practice. 
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Data of HPP in various studies   
FPP  
n (%) 
SPP 
 n (%) 
Mean age at 
onset yrs M:F 
Lin SH et al 200114 2(2) 29(30) 21 25:6 
Lin SH et al 20042 1(2) 9(21) 27 9:1 
Rao et al1 0 2(6) 13 2:0 
Maurya et al43 0 17(57) 32 17:0 
Phakdeekitcharoen et 
al42 5(15) 10(29) 22 13:2 
Our study 0 20(43) 25 15:5 
  
 In our study 20 patients (43%) had SPP, none had family history of 
periodic paralysis. The mean age of onset was 24.6±5.7 yrs with a male 
preponderance 15:5. The mean duration of weakness was 22.7±5 hrs. The mean 
potassium chloride (both oral and intravenous) required for recovery of paralysis 
in this group is 58±23 mmols (range 20-110 mmols). None had urinary loss of 
potassium in this group. 
 Three patients had respiratory paralysis in this group. Thirteen patients 
noticed weakness while getting up from bed in the morning, 1 patient noticed 
weakness after recovering from alcohol binge. Limb muscles were more affected 
than the trunk muscles. Those who had respiratory paralysis and muscle power 
≤3/5 where treated with intravenous potassium chloride and others were treated 
with oral potassium supplementation. All patients were started on acetazolamide 
or spiranolactone prophylaxis. Four patients in this group had recurrence 
between 4-10 weeks after discontinuation of prophylaxis.   
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Data of TPP in various studies   
 
  n (%)  Mean Age
Yrs 
M/F  T3(nmol/L) T4 (nmol/L) 
Lin SH et al 200114  39(40) 28 39:0 4.5±0.2 201±33 
Lin SH et al 20042  20(47) 28 20:0  
Rao et al1  2(6) 36 2:0  
Maurya et al43  5(17) 36 5:0  
Phakdeekitcharoen et al42  11(32) 32  10:1
 
 
Philip Wong et al46  10  34  9:1   
Our study  4(9) 43 3:1 5.7±0.1 196.25±5 
 
 We had 4 patients (9%) with TPP with a mean age of 43 yrs, M: F, 3:1. 
The incidence of TPP is highest in Asian population which accounted 80% in 
Hong Kong18 and 40% in Taiwan.14 But TPP is not the most common causes in 
our study and other Indian studies. 43,1 All the four patients in our study had 
tachycardia without any overt thyrotoxic symptoms. These findings  in our study 
are in conformity with other studies which states that TPP affects males more 
than females although thyrotoxicosis is common in females and most patients 
have only mild or no symptoms of thyrotoxicosis . 46, 47 These patients were 
managed with oral potassium and propranolol followed by definitive therapy for 
thyrotoxicosis. We did not see recurrences in this group of patients. 
 
 
58 
 
 
Data of RTA patients in various studies   
 
 The cause of HP in 16 patients (33%) in our series was Renal tubular 
acidosis (15- distal RTA and 1- proximal RTA), 7 patients had Sjogren’s 
syndrome. All the patients had high renal potassium excretion (U K+/Cr 
4.35±0.8). As shown above the patients with RTA were predominantly females 
with mean age of 37 yrs. Mean time to improve was higher (31.3±6.2 Vs 
22.7±5.07 hrs) than SPP, and required more potassium supplementation 
(101.3±18.8 Vs 58±23 mmols) for paralysis recovery than in SPP. Two patients 
had respiratory paralysis which improved after potassium supplementation. Pun 
et al described 26 patients with Sjogren’s syndrome, 3 had HP and distal RTA 
which preceded diagnosis of Sjogren’s syndrome by 2-8 years. 49 
 
 
 
 
 
  No of patients Mean Age
 Yrs 
M:F Sjogrens  Nephro
calcinosis
  p RTA d RTA    
LIN SH et al 200114  0  6  47  3:3 3   
LIN SH et al 20042  1 5 39 3:3 4   
Rao et al1  10  3  33  9:4 3   
Maurya et al43  1  3  27  1:3    
Phakdeekitcharoen et al42  0  8  41  1:3   3 
Our study  1  15  37  4:12 7  2 
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Data of GS patients in various studies   
 
n (%) Mean Age M:F 
Lin SH et al 200114 6(6) 21 4:2 
Lin SH et al 20042 4(9) 24 3:1 
Rao et al1 1(3) 68 1:0 
Maurya et al43 4(13) 29 4:0 
Phakdeekitcharoen et al42 0 
Our study 6(13) 35 5:1 
 
 In our series 6 (13%) had Gitelman’s syndrome, mean age 34.67±3.1yrs, 
with 5 males and 1 female. These patients had low serum chloride (97.83±5.8 Vs 
105±13.5 mEq/l) than SPP. Two of our patients had history of tetany with low 
serum calcium (7.8 and 8.5 mg/dl). None had respiratory paralysis.  
 In Lin SH et al (2001)14 series they reported 6 cases of 
Bartter’s/Gitelman’s, individual case reports of Bartter’s syndrome with HP 
were reported50. None of our patients had Bartter’s syndrome. 
  GS patients were treated with magnesium and potassium 
supplementation. Potassium sparing diuretics and indomethacin can also be 
used.41, 51 It is essential to correct hypomagnesemia along with hypokalemia, 
otherwise hypokalemia will be resistant to correct if there is underlying 
magnesium deficiency. 41 
 In our study one male patient who presented with HP had Liddle’s 
syndrome, he was diagnosed to have hypertension about one year before 
presentation. He had  recurrent episodes of HP in the year 2009. BP remained 
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high despite being on 4 antihypertensives (telmesartan, thiazide, prazosin, 
metaprolol). He had metabolic alkalosis with urinary potassium loss, low plasma 
renin activity and low aldosterone. He had good response to triamterene and did 
not have recurrence. There are case reports of muscle weakness52 and periodic 
paralysis53 in Liddle’s syndrome.  
 In our study three patients had rebound hyperkalemia (>5 mEq/L), two 
patients in SPP and one patient in TPP groups. None of the patients in Non- HPP 
(large K+ deficit) group had rebound hyperkalemia. In Lin SH et al (2004)2 series 
19 of 30 patients in the HPP group developed rebound hyperkalemia. 
 Since this study is from a single tertiary referral centre, only those 
patients with severe or recurrent episodes may have been seen by us. This is a 
limitation of our study. 
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CONCLUSIONS 
 
 
1. The commonest causes for hypokalemic paralysis (HP) in our study were 
sporadic periodic paralysis (SPP) and renal tubular acidosis (RTA). 
 
2. Among the patients with hypokalemic paralysis, 57% of them were due to 
secondary causes. Presence of acidosis or alkalosis in arterial blood gas 
analysis suggests a renal cause for Hypokalemic paralysis. 
 
3. Spot urine K+/Cr ratio helps to distinguish the diagnostic categories of 
HPP (Hypokalemic paralysis due to K+  shifts) with non-HPP 
(Hypokalemic paralysis due to K+  deficits) 
 
4. There was a male predominance in Hypokalemic periodic paralysis 
(HPP). Sporadic periodic paralysis (SPP) was more common than familial 
periodic paralysis (FPP) in this study. 
 
5. Male predominance was noted in Thyrotoxic periodic paralysis ( TPP). 
Absence of history of thyroid disease or clinical thyrotoxicosis does not 
exclude the diagnosis of TPP. So thyroid function tests should be done in 
all patients with HP. 
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6. Though much less potassium is needed during therapy of HPP (SPP, 
TPP), there is still a danger of rebound hyperkalemia. 
 
7. Hypomagnesemia should be looked for and corrected along with the 
correction of hypokalemia in patients with metabolic alkalosis. 
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16  18  61  M  1  26  80  N  1.8  138  102  26  0.7  3.6  8.9  7.38  42  20  106  7  6.2  1.13  5.6  89  3.9  96  120/80  SPP  Y  N 
17  20  53  M  3  19  170  23  Y  1.8  137  85  20  0.8  3.5  9.5  7.38  42  22.2  99  12  8.4  1.43  5.6  78  4  <5.5  95  120/80  NIL  SPP  N 
18  21  51  M  2  22  60  3  N  3  134  98  18  0.7  3.6  8.9  7.4  36  22  100  11  5.6  1.96  212  6.2  112  5.8  82  130/80  SPP  N 
19  22  43  F  1  24  40  N  2.6  134  79  18  0.55  3.4  8.5  7.36  36  23  106  12  6.7  1.79  5.7  78  5.2  99  110/70  SPP  N 
20  20  62  M  2  34  90  3  N  3.1  133  90  22  0.7  3.5  8.8  7.39  41  23  105  11  6.2  1.77  5.6  96  4.5  87  110/80  SPP  Y  N 
21  19  49  M  6  22  160  24  Y  1.9  138  92  26  0.9  2.8  9.1  7.39  41.2  23.9  107  12  6.3  1.90  5.7  98  5.2  78  120/80  SPP  N 
22  19  45  M  2  20  50  2  N  2  135  99  24  0.7  2.9  9.2  7.38  42  22.3  109  13  8.2  1.59  5.8  89  5.6  96  110/70  SPP  5.1 
23  23  52  M  3  28  160  7  Y  2  136  85  25  8  4  8.5  7.36  36.9  22  101  9.5  5.78  1.64  5.9  79  7  79  120/80  SPP  N 
24  32  48  F  2  18  60  2  N  2.9  134  89  20  0.6  2.8  8.8  7.35  35.8  22.9  108  12  8.2  1.46  5.7  88  5.6  102  110/70  SPP  N 
25  30  54  M  2  20  70  3  N  3.2  133  88  24  0.7  3.6  8.5  7.39  41  23  105  11  8.2  1.34  5.6  96  4.5  85  110/80  SPP  N 
26  25  52  M  2  21  30  3  N  1.9  140  98  23  0.9  2.8  9  7.38  42.6  22.6  109  12  6.5  1.85  6.1  95  3.8  102  120/80  SPP  N 
27  26  49  F  2  18  30  5  N  3  141  96  18  0.6  3.5  9.3  7.38  41.4  24.4  108  16  6.6  2.42  214  5.6  82  4  86  120/80  SPP  N 
28  19  56  M  2  15  40  1  N  2.9  135  102  22  0.9  3.6  8.5  7.41  43  24.1  102  14  6.2  2.26  245  5.7  99  5.9  75  130/80  SPP  N 
29  22  50  M  2  19  60  5  N  2.9  140  102  21  0.8  3.4  8.6  2.1  7.40  37.1  24.1  111  14  5.8  2.41  5.6  87  5.6  75  130/80  SPP  N 
30  35 
62 
M  1  32  120  N  2.5  135  96  25  0.8  4.1  8.9  1.6  7.46  37  26.5  105  25.6  4.8  5.33  167  110  5.6  79  3.9  84  130/80  GS  N 
31  36 
71 
M  2  38  100  14  N  3.1  136  95  26  0.8  2.9  8.9  1.2  7.5  44.5  34  89  31  5.8  5.34  116  127.5  5.9  89  5.4  78  120/80  GS  Y  N 
32  37 
54 
M  2  47  80  14  N  2.8  135  109  19  0.7  3.8  8.5  0.9  7.45  41.5  27.8  103  28  3.9  7.18  52  105  5.8  102  5.6  82  130/80  GS  N 
33  32 
61 
M  1  30  90  N  3  126  92  24  1  3.7  7.8  0.87  7.42  46.1  29  98  36  7.8  4.62  76  123  6  96  7.5  89  130/80  GS  N 
34  30 
64 
M  1  36  80  N  1.9  136  99  25  0.9  3.3  9.1  1.4  7.48  42.3  28.5  98  42  6  7.00  121  109  5.9  85  6  98  120/80  GS  N 
35  38 
51 
F  2  42  70  16  N  2.5  135  88  26  0.9  2.8  9  1.5  7.47  42.1  29.8  94  22.9  5.9  3.88  56  103  5.9  103  4.2  82  130/80  GS  N 
36  41  50  F  3  23  90  14  N  2.1  140  113  23  0.8  4  8.8  2  7.24  26.6  11.3  123  40.3  7.3  5.52  6.6  84  5.4  POS  >5.5  96  120/80  NIL  12  d RTA/SJ  N 
37  48  52  F  1  32  90  N  3  136  73  24  0.7  4.2  8.5  1.9  7.33  27  14  112  32  7.9  4.05  5.6  78  5.4  POS  >5.5  95  120/70  NIL  14  d RTA/SJ  N 
38  47  49  M  2  30  100  1  N  2  140  109  18  0.6  3.8  8.6  1.8  7.33  27.9  15  115  26  5.72  4.55  5.9  82  6.1  POS  >5.5  82  110/70  NIL  9.1  d RTA/SJ  N 
39  30  45  F  4  41  110  6  N  2.5  138  99  20  0.7  3.2  8.9  2  7.24  36.7  15.6  110  32  6.2  5.16  5.6  89  4.5  POS  99  120/70  NIL  7.8  d RTA/SJ  N 
40  36  46  F  2  24  80  2  N  2.9  139  80  22  0.7  3  8.8  2.1  7.26  39.2  16.8  102  29  6.3  4.60  5.6  98  5.6  POS  87  110/70  NIL  11  d RTA/Sj  N 
41  40  60  F  3  35  90  24  N  2  139  95  24  0.9  4.1  8.5  2.3  7.23  30.1  15.1  103  22  8.2  2.68  5.9  82  5.6  POS  >5.5  79  110/70  NIL  15.2  d RTA/SJ  N 
42  50  58  F  3  24  80  4  N  2.6  138  102  24  0.7  3.2  8.6  2  7.22  35.6  14.3  107  23  5.78  3.98  5.7  75  3.2  POS  <5.5  89  110/70  NIL  26  p RTA/SJ  N 
43  49  54  M  2  28  70  10  N  2.3  140  102  26  0.7  3.4  8.6  7.36  39.3  23.6  110  16  8.8  1.82  5.8  202  11.8  102  120/80  TPP  N 
44  30  52  M  2  21  80  3  N  2.9  138  102  24  0.7  3  9.2  7.38  41.8  21.8  108  15  6.2  2.42  5.7  198  8.9  112  120/80  TPP  N 
45  45  61  F  1  27  40  N  2.9  138  90  24  1  2.9  9  7.38  42  24.1  104  12  6.5  1.85  5.9  226.5  16  110  130/80  TPP  5.2 
46  48  53  M  1  19  40  N  3.1  132  79  25  0.9  2.8  9.5  7.38  41.2  23.6  98  16  7.1  2.25  5.6  195  12.1  108  120/80  TPP  N 
47  32  54  M  3  12  50  3  N  1.8  144  78  26  1  3  9  2.3  7.58  35  37  103  28  5.3  5.28    201  6.5  78  4      78  160/100      LIDDLE    N 
 
PROFORMA 
 
1. Name:     NC  No.:     DOA: 
     
2. Age:     Sex:      
        
3. Occupation: 
4. Address: 
 
5. Presenting History: 
 
a. Vomiting: 
b. Diarrhoea: 
c. Drugs: 
d. Laxative abuse: 
e. Other predisposing Factors: 
f. Fever:  
g. Polyuria: 
h. Dry eyes: 
i. Dry mouth: 
6. Family History: 
 
7. Examination: 
  Rt Lt 
Power 
UL   
LL   
DTR 
UL   
LL   
Neck muscles  
Resp Paralysis  
 
 
 
 
 
 
8. Vital signs: 
Pulse:     BP:    RR: 
a. Systems: 
 
 
 
9. Previous episodes: 
 
 
 
10. Treatment: 
 
 
 
 
11. Investigations : 
 
Sl No. Test     
1 ECG    
2 TC    
3 DC    
4 ESR    
5 Hb    
6 UREA    
7 CREATININE    
8 B.SUGAR    
9 Sr Na    
10 Sr K    
11 Sr Po4    
12 Sr calcium    
13 Sr uric acid    
14 Sr osmolality    
15 ABG    
   
   
   
16 URINALYSIS    
 Protein    
Sugar    
Deposits    
17 URINE CULTURE    
18 URINE pH    
19 URINE K    
20 URINE Cl    
21 URINE PO4    
22 URINE UA    
23 Urine amino acids    
24 Urine osmolality    
25 TTKG    
26 24 urine Ca    
27 Ca/Cr Ratio    
28 Sr Mg    
29 NCS    
30 Thyroid profile    
31 U Acidification test    
  ABG    
  Urine pH    
32 KUB    
33 USG    
34 CT KUB    
35     
36     
37     
38     
39     
40     
 
Diagnosis 
Follow up 
